Key result
This editorial summarizes recent research on antiarrhythmic drug therapies, highlighting disappointing past results and discussing new potential targets such as late sodium current and CaMKII.
Answers are grounded in this paper and cite their sources.
This editorial reviews the historical challenges of antiarrhythmic drug therapy and introduces emerging research directions focusing on cellular electrophysiology and calcium handling.
Disappointing Past, Current Efforts, and Faint HopesPresent issue is devoted to those areas of cardiac electrophysiology, pathophysiology, and pharmacology which are critically important to improve the efficacy of antiarrhythmic treatment.Cardiac arrhythmia is a leading cause of morbidity and mortality, and the history of anti-arrhythmic drug therapies has been dismal.Development of apparently more and more selective and effective antiarrhythmic agents has been in the focus of interest of drug research in the past few decades, however, neither the ideal compound, nor an optimal strategy could be demonstrated so far.Furthermore, disappointing results have been obtained with several old antiarrhythmic agents, like many class I/C and class III drugs as documented by the CAST (Investigators of the Cardiac Arrhythmia Suppression Trial Preliminary report, 1989) and SWORD (Waldo et al., 1995) studies, respectively.The direct proarrhythmic side-effects of many currently applied antiarrhythmic agents are evident by now.Some "malpractices" in the past, however, could have been prevented by studying the actions of conventional antiarrhythmic compounds systematically in a frequencydependent manner.One approach may be studying the kinetics of electrical restitution of action potential duration (APD) as presented by A ́rpadffy-Lovas et al. in this issue.They studied the restitution kinetics of APD in many species, including humans, and concluded that in addition to basic APD, some ion currents, like I Na or I to , may also modify restitution kinetics.Due to the insufficient therapeutic results in the past we are continuously trying to find new trails, new antiarrhythmic mechanisms (each of them, of course, will also carry its own pitfalls), such as the suppression of late Na + current, application of Na + /Ca 2+ exchanger blockers, or selective manipulation of CaMKII activity.All these ideas are discussed in the present issue in details.Better understanding of the proarrhythmic mechanisms may minimize the unwanted side-effects and yield better therapeutic results.Accordingly, having a deeper insight into the properties of the finely tuned myocardial Ca 2+ -handling, its regulatory and modulatory role in the entire cardiac electrogenesis, including action potential morphology, pacemaker activity, and arrhythmogenesis, may allow the development of novel antiarrhythmic strategies.The role of pathological Ca 2+ handling in development of cardiac arrhythmias is reviewed in this issue by Kistamaś et al.
No takes yet. Share an insight, caveat, or question.
Nánási et al. (2020) conducted an editorial in Cardiac arrhythmias. Antiarrhythmic drug therapy was evaluated. This editorial summarizes recent research on antiarrhythmic drug therapies, highlighting disappointing past results and discussing new potential targets such as late sodium current and CaMKII.
Synapse has enriched 10 related papers. Consider them for comparative context: